Roche acquires non US rights to SRP 9001 from Sarepta Therapeutics, a treatment for Duchenne muscular dystrophy.

Roche and Sarepta Therapeutics, Inc. announced the signing of a licensing agreement providing Roche exclusive commercial rights to SRP 9001 (AAVrh74.MHCK7.micro-dystrophin), Sarepta�s investigational gene therapy for Duchenne muscular dystrophy (DMD), outside the United States.

Under the terms of the agreement, Sarepta will receive an upfront payment of $750 million in cash and $400 million in equity. In addition, Sarepta is eligible to receive regulatory and sales milestones, and royalties on net sales. Roche and Sarepta will equally share global development expenses. This collaboration demonstrates Roche's commitment to gene therapy and its transformational potential for patients. It combines Roche�s global reach, commercial presence and regulatory expertise with Sarepta�s gene therapy candidate for DMD to accelerate access to SRP 9001 for patients outside the United States.

DMD is an X-linked rare degenerative neuromuscular disorder causing severe progressive muscle loss and premature death. SRP 9001, currently in clinical development for DMD, is designed to deliver the microdystrophin-encoding gene directly to the muscle tissue for the targeted production of the microdystrophin protein.